Merck withdraws arthritis drug worldwide
The pharmaceutical company Merck last week initiated a voluntary immediate worldwide withdrawal of its bestselling arthritis drug rofecoxib (Vioxx), because new research shows that it almost doubles the risk of myocardial infarction and stroke if taken for 18 months or more. Rofecoxib, a cyclo-oxyge...
Gespeichert in:
| Veröffentlicht in: | BMJ 2004-10, Vol.329 (7470), p.816-816 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 816 |
|---|---|
| container_issue | 7470 |
| container_start_page | 816 |
| container_title | BMJ |
| container_volume | 329 |
| creator | Singh, Debashis |
| description | The pharmaceutical company Merck last week initiated a voluntary immediate worldwide withdrawal of its bestselling arthritis drug rofecoxib (Vioxx), because new research shows that it almost doubles the risk of myocardial infarction and stroke if taken for 18 months or more. Rofecoxib, a cyclo-oxygenase-2 selective inhibitor, has been on the market since 1999 and is used by 2 million people in over 80 countries worldwide with 400 000 taking it in the United Kingdom. It is indicated for osteoarthritis and rheumatoid arthritis, and higher dose strengths are indicated for short term relief of acute pain (VioxxAcute). The new study, called APPROVe (adenomatous polyp prevention on Vioxx), was a multicentre, randomised placebo controlled double blind trial to determine the effect of three years of treatment with rofecoxib on the recurrence of neoplastic polyps of the large bowel in patients with a history of colorectal adenoma. [PUBLICATION ABSTRACT] |
| doi_str_mv | 10.1136/bmj.329.7470.816-a |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_521598</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>25458364</jstor_id><sourcerecordid>25458364</sourcerecordid><originalsourceid>FETCH-LOGICAL-b550t-da7e0060c3bf1dbb71c3e216bdb60aeab0dd93d7600a3a26eab4626f666f562f3</originalsourceid><addsrcrecordid>eNqNkU1PGzEURS1UBBHwB5BaRe2mmwnPX88ziy6qqJRWUIREu2DzZI89ZEKSofaEtP8eR4lCu6jU1Ui-53qOfBk75TDiXOKZm09HUlQjowyMSo6F3WMDrrAsdCnlKzaASldFyWV5yE5SmgKAkKasUB-wQ66VEULpAXt_FWL9MFy1_cRHu0pDG_tJbPs2DX1c3g9XXZz5VevDMdtv7CyFk-33iH0__3Q7vigurz9_GX-8LJzW0BfemgCAUEvXcO-c4bUMgqPzDsEG68D7SnqDAFZagflEocAGERuNopFH7MPm3selmwdfh0Uf7YweYzu38Td1tqW_k0U7ofvuibTguipz_-22H7ufy5B6mnbLuMjKJECB4KZUGXr3L4gbY1BoxWWmxIaqY5dSDM3OggOtR6A8AuURaD0C5RHI5tKbP_1fKtsnz8DrDTBNfRd3ef5lHg7XbsUmb1Mffu1yGx8IjTSavv0Y051RQsPNLX194dcy_yH4DBqLqgU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1777625413</pqid></control><display><type>article</type><title>Merck withdraws arthritis drug worldwide</title><source>Applied Social Sciences Index & Abstracts (ASSIA)</source><source>Jstor Complete Legacy</source><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Singh, Debashis</creator><creatorcontrib>Singh, Debashis</creatorcontrib><description>The pharmaceutical company Merck last week initiated a voluntary immediate worldwide withdrawal of its bestselling arthritis drug rofecoxib (Vioxx), because new research shows that it almost doubles the risk of myocardial infarction and stroke if taken for 18 months or more. Rofecoxib, a cyclo-oxygenase-2 selective inhibitor, has been on the market since 1999 and is used by 2 million people in over 80 countries worldwide with 400 000 taking it in the United Kingdom. It is indicated for osteoarthritis and rheumatoid arthritis, and higher dose strengths are indicated for short term relief of acute pain (VioxxAcute). The new study, called APPROVe (adenomatous polyp prevention on Vioxx), was a multicentre, randomised placebo controlled double blind trial to determine the effect of three years of treatment with rofecoxib on the recurrence of neoplastic polyps of the large bowel in patients with a history of colorectal adenoma. [PUBLICATION ABSTRACT]</description><edition>International edition</edition><identifier>ISSN: 0959-8138</identifier><identifier>ISSN: 0959-8146</identifier><identifier>EISSN: 1468-5833</identifier><identifier>EISSN: 1756-1833</identifier><identifier>DOI: 10.1136/bmj.329.7470.816-a</identifier><identifier>PMID: 15472245</identifier><identifier>CODEN: BMJOAE</identifier><language>eng</language><publisher>England: British Medical Journal Publishing Group</publisher><subject>Arthritis ; Arthritis - drug therapy ; Cyclooxygenase 2 ; Cyclooxygenase 2 Inhibitors ; Cyclooxygenase Inhibitors - adverse effects ; Drug Approval ; Drug Industry - legislation & jurisprudence ; Health risk assessment ; Heart attacks ; Humans ; Isoenzymes - antagonists & inhibitors ; Lactones - adverse effects ; Membrane Proteins ; News ; Pharmaceuticals ; Product recalls ; Prostaglandin-Endoperoxide Synthases ; Stroke ; Sulfones ; Thromboembolism - chemically induced</subject><ispartof>BMJ, 2004-10, Vol.329 (7470), p.816-816</ispartof><rights>2004 BMJ Publishing Group Ltd.</rights><rights>Copyright 2004 BMJ Publishing Group Ltd</rights><rights>Copyright: 2004 (c) 2004 BMJ Publishing Group Ltd.</rights><rights>Copyright BMJ Publishing Group Oct 9, 2004</rights><rights>Copyright © 2004, BMJ Publishing Group Ltd. 2004</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b550t-da7e0060c3bf1dbb71c3e216bdb60aeab0dd93d7600a3a26eab4626f666f562f3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/25458364$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/25458364$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>230,314,776,780,799,881,27901,27902,30976,57992,58225</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15472245$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Singh, Debashis</creatorcontrib><title>Merck withdraws arthritis drug worldwide</title><title>BMJ</title><addtitle>BMJ</addtitle><description>The pharmaceutical company Merck last week initiated a voluntary immediate worldwide withdrawal of its bestselling arthritis drug rofecoxib (Vioxx), because new research shows that it almost doubles the risk of myocardial infarction and stroke if taken for 18 months or more. Rofecoxib, a cyclo-oxygenase-2 selective inhibitor, has been on the market since 1999 and is used by 2 million people in over 80 countries worldwide with 400 000 taking it in the United Kingdom. It is indicated for osteoarthritis and rheumatoid arthritis, and higher dose strengths are indicated for short term relief of acute pain (VioxxAcute). The new study, called APPROVe (adenomatous polyp prevention on Vioxx), was a multicentre, randomised placebo controlled double blind trial to determine the effect of three years of treatment with rofecoxib on the recurrence of neoplastic polyps of the large bowel in patients with a history of colorectal adenoma. [PUBLICATION ABSTRACT]</description><subject>Arthritis</subject><subject>Arthritis - drug therapy</subject><subject>Cyclooxygenase 2</subject><subject>Cyclooxygenase 2 Inhibitors</subject><subject>Cyclooxygenase Inhibitors - adverse effects</subject><subject>Drug Approval</subject><subject>Drug Industry - legislation & jurisprudence</subject><subject>Health risk assessment</subject><subject>Heart attacks</subject><subject>Humans</subject><subject>Isoenzymes - antagonists & inhibitors</subject><subject>Lactones - adverse effects</subject><subject>Membrane Proteins</subject><subject>News</subject><subject>Pharmaceuticals</subject><subject>Product recalls</subject><subject>Prostaglandin-Endoperoxide Synthases</subject><subject>Stroke</subject><subject>Sulfones</subject><subject>Thromboembolism - chemically induced</subject><issn>0959-8138</issn><issn>0959-8146</issn><issn>1468-5833</issn><issn>1756-1833</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><sourceid>7QJ</sourceid><recordid>eNqNkU1PGzEURS1UBBHwB5BaRe2mmwnPX88ziy6qqJRWUIREu2DzZI89ZEKSofaEtP8eR4lCu6jU1Ui-53qOfBk75TDiXOKZm09HUlQjowyMSo6F3WMDrrAsdCnlKzaASldFyWV5yE5SmgKAkKasUB-wQ66VEULpAXt_FWL9MFy1_cRHu0pDG_tJbPs2DX1c3g9XXZz5VevDMdtv7CyFk-33iH0__3Q7vigurz9_GX-8LJzW0BfemgCAUEvXcO-c4bUMgqPzDsEG68D7SnqDAFZagflEocAGERuNopFH7MPm3selmwdfh0Uf7YweYzu38Td1tqW_k0U7ofvuibTguipz_-22H7ufy5B6mnbLuMjKJECB4KZUGXr3L4gbY1BoxWWmxIaqY5dSDM3OggOtR6A8AuURaD0C5RHI5tKbP_1fKtsnz8DrDTBNfRd3ef5lHg7XbsUmb1Mffu1yGx8IjTSavv0Y051RQsPNLX194dcy_yH4DBqLqgU</recordid><startdate>20041009</startdate><enddate>20041009</enddate><creator>Singh, Debashis</creator><general>British Medical Journal Publishing Group</general><general>British Medical Association</general><general>BMJ Publishing Group LTD</general><general>BMJ Publishing Group</general><general>BMJ Group</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ASE</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FPQ</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K6X</scope><scope>K9.</scope><scope>LK8</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7QJ</scope><scope>5PM</scope></search><sort><creationdate>20041009</creationdate><title>Merck withdraws arthritis drug worldwide</title><author>Singh, Debashis</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b550t-da7e0060c3bf1dbb71c3e216bdb60aeab0dd93d7600a3a26eab4626f666f562f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Arthritis</topic><topic>Arthritis - drug therapy</topic><topic>Cyclooxygenase 2</topic><topic>Cyclooxygenase 2 Inhibitors</topic><topic>Cyclooxygenase Inhibitors - adverse effects</topic><topic>Drug Approval</topic><topic>Drug Industry - legislation & jurisprudence</topic><topic>Health risk assessment</topic><topic>Heart attacks</topic><topic>Humans</topic><topic>Isoenzymes - antagonists & inhibitors</topic><topic>Lactones - adverse effects</topic><topic>Membrane Proteins</topic><topic>News</topic><topic>Pharmaceuticals</topic><topic>Product recalls</topic><topic>Prostaglandin-Endoperoxide Synthases</topic><topic>Stroke</topic><topic>Sulfones</topic><topic>Thromboembolism - chemically induced</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Singh, Debashis</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Index</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>British Nursing Index</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>Applied Social Sciences Index & Abstracts (ASSIA)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BMJ</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Singh, Debashis</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Merck withdraws arthritis drug worldwide</atitle><jtitle>BMJ</jtitle><addtitle>BMJ</addtitle><date>2004-10-09</date><risdate>2004</risdate><volume>329</volume><issue>7470</issue><spage>816</spage><epage>816</epage><pages>816-816</pages><issn>0959-8138</issn><issn>0959-8146</issn><eissn>1468-5833</eissn><eissn>1756-1833</eissn><coden>BMJOAE</coden><abstract>The pharmaceutical company Merck last week initiated a voluntary immediate worldwide withdrawal of its bestselling arthritis drug rofecoxib (Vioxx), because new research shows that it almost doubles the risk of myocardial infarction and stroke if taken for 18 months or more. Rofecoxib, a cyclo-oxygenase-2 selective inhibitor, has been on the market since 1999 and is used by 2 million people in over 80 countries worldwide with 400 000 taking it in the United Kingdom. It is indicated for osteoarthritis and rheumatoid arthritis, and higher dose strengths are indicated for short term relief of acute pain (VioxxAcute). The new study, called APPROVe (adenomatous polyp prevention on Vioxx), was a multicentre, randomised placebo controlled double blind trial to determine the effect of three years of treatment with rofecoxib on the recurrence of neoplastic polyps of the large bowel in patients with a history of colorectal adenoma. [PUBLICATION ABSTRACT]</abstract><cop>England</cop><pub>British Medical Journal Publishing Group</pub><pmid>15472245</pmid><doi>10.1136/bmj.329.7470.816-a</doi><tpages>1</tpages><edition>International edition</edition><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0959-8138 |
| ispartof | BMJ, 2004-10, Vol.329 (7470), p.816-816 |
| issn | 0959-8138 0959-8146 1468-5833 1756-1833 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_521598 |
| source | Applied Social Sciences Index & Abstracts (ASSIA); Jstor Complete Legacy; MEDLINE; Alma/SFX Local Collection |
| subjects | Arthritis Arthritis - drug therapy Cyclooxygenase 2 Cyclooxygenase 2 Inhibitors Cyclooxygenase Inhibitors - adverse effects Drug Approval Drug Industry - legislation & jurisprudence Health risk assessment Heart attacks Humans Isoenzymes - antagonists & inhibitors Lactones - adverse effects Membrane Proteins News Pharmaceuticals Product recalls Prostaglandin-Endoperoxide Synthases Stroke Sulfones Thromboembolism - chemically induced |
| title | Merck withdraws arthritis drug worldwide |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T10%3A55%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Merck%20withdraws%20arthritis%20drug%20worldwide&rft.jtitle=BMJ&rft.au=Singh,%20Debashis&rft.date=2004-10-09&rft.volume=329&rft.issue=7470&rft.spage=816&rft.epage=816&rft.pages=816-816&rft.issn=0959-8138&rft.eissn=1468-5833&rft.coden=BMJOAE&rft_id=info:doi/10.1136/bmj.329.7470.816-a&rft_dat=%3Cjstor_pubme%3E25458364%3C/jstor_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1777625413&rft_id=info:pmid/15472245&rft_jstor_id=25458364&rfr_iscdi=true |